FindTrial
Sign In

Establishment and validation of irAEs risk prediction model in ICI induced tumor patients

Establishment and validation of irAEs risk prediction model in ICI induced tumor patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400079727
Enrollment
Unknown
Registered
2024-01-10
Start date
2024-01-10
Completion date
Unknown
Last updated
2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

modeling group:none
internal validation:none
external validation:none

Sponsors

Department of Pharmacy, the First Affiliated Hospital of Shihezi University, Xinjiang
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1 Age =18 years; 2 Patients with advanced malignant tumors treated with ICI (the main study cancers were non-small cell lung cancer, gastric cancer, colorectal cancer, and esophageal cancer of the liver); 3 A clear diagnosis with complete clinicopathological data;4 ECOG/PS score <3; and 5 Informed consent.

Exclusion criteria

Exclusion criteria: 1 Severe or active autoimmune disease;2 Treatment regimen of less than one cycle;3 Pregnancy or severe infection.

Design outcomes

Primary

MeasureTime frame
irAEs;—

Secondary

MeasureTime frame
PFS;OS;—

Countries

China

Contacts

Public ContactLi Jing

Department of Pharmacy, the First Affiliated Hospital of Shihezi University, Xinjiang

1581570708@qq.com+86 135 7974 8690

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026